ZIVO vs. EVAX, AIM, APTO, PMCB, SNTI, PLUR, TVGN, BCLI, CRTX, and ACHL
Should you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include Evaxion Biotech A/S (EVAX), AIM ImmunoTech (AIM), Aptose Biosciences (APTO), PharmaCyte Biotech (PMCB), Senti Biosciences (SNTI), Pluri (PLUR), Tevogen Bio (TVGN), Brainstorm Cell Therapeutics (BCLI), Cortexyme (CRTX), and Achilles Therapeutics (ACHL). These companies are all part of the "medical" sector.
ZIVO Bioscience (NASDAQ:ZIVO) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.
ZIVO Bioscience's return on equity of 0.00% beat Evaxion Biotech A/S's return on equity.
In the previous week, Evaxion Biotech A/S had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 1 mentions for Evaxion Biotech A/S and 0 mentions for ZIVO Bioscience. Evaxion Biotech A/S's average media sentiment score of 0.67 beat ZIVO Bioscience's score of 0.00 indicating that Evaxion Biotech A/S is being referred to more favorably in the news media.
ZIVO Bioscience received 82 more outperform votes than Evaxion Biotech A/S when rated by MarketBeat users. Likewise, 61.11% of users gave ZIVO Bioscience an outperform vote while only 56.67% of users gave Evaxion Biotech A/S an outperform vote.
12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 11.0% of Evaxion Biotech A/S shares are held by institutional investors. 13.4% of ZIVO Bioscience shares are held by insiders. Comparatively, 41.6% of Evaxion Biotech A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
ZIVO Bioscience has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Evaxion Biotech A/S has a beta of -0.22, meaning that its share price is 122% less volatile than the S&P 500.
Evaxion Biotech A/S has a consensus target price of $11.00, indicating a potential upside of 181.33%. Given Evaxion Biotech A/S's higher possible upside, analysts clearly believe Evaxion Biotech A/S is more favorable than ZIVO Bioscience.
ZIVO Bioscience has higher earnings, but lower revenue than Evaxion Biotech A/S. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Evaxion Biotech A/S, indicating that it is currently the more affordable of the two stocks.
Summary
ZIVO Bioscience and Evaxion Biotech A/S tied by winning 8 of the 16 factors compared between the two stocks.
Get ZIVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZIVO Bioscience Competitors List
Related Companies and Tools
